Accéder au contenu
Merck

14-475-M

Cdk2/Cyclin E Protein, active, 10 µg

Active complex of recombinant full length human Cdk2 containing a C-terminal His6-tag & recombinant full-length human Cyclin E containing an N-terminal GST-tag. For use in Kinase Assays.

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

UNSPSC Code:
12352202
NACRES:
NA.41
eCl@ss:
32160405
Biological source:
human
Recombinant:
expressed in baculovirus infected Sf21 cells
Mol wt:
Mw 34 kDa (cdk2), Mw 74 kDa (cyclin)
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider


biological source

human

Quality Level

recombinant

expressed in baculovirus infected Sf21 cells

shelf life

1 yr

mol wt

Mw 34 kDa (cdk2), Mw 74 kDa (cyclin)

manufacturer/tradename

Upstate®

technique(s)

activity assay: suitable (kinase)

solubility

water: soluble

NCBI accession no.

UniProt accession no.

Gene Information

human ... CCNE1(898), CDK2(898)

General description

Research area: APOPTOSIS

Complex of recombinant full length human cdk2 containing a C-terminal His6-tag, and recombinant full-length human cyclin E containing an N-terminal GST-tag. Product Source: Both are expressed by baculovirus in Sf21 insect cells The Cyclin E genes (CCNE1) gene located at 19q12 region in humans is responsible for encoding full-length protein of 410 amino acids.

Biochem/physiol Actions

Protein Target: CDK2/cyclinE

Target Sub-Family: CMGC

The Cyclin E1 protein binds to and activates Cyclin-dependent kinase 2 (CDK2), forming an active complex crucial for the initiation and progression of the S phase. Cyclin E/CDK2 complex primarily regulates cell cycle advancement and DNA replication by phosphorylating specific substrates. Elevated Cyclin E protein levels and heightened CDK2 kinase activity are both individually linked to unfavorable prognosis, decreased survival, and resistance to therapy in cancer patients. Overactivation of the Cyclin E/CDK2 complex directly disrupts DNA replication through multiple mechanisms, resulting in DNA double strand breaks (DSBs) and genomic instability. Targeting the oncogenic Cyclin E/CDK2 complex has emerged as a potential therapeutic approach against cancer.

Packaging

Also available in 250μg size as catalog # 14-475M - Call for pricing and availability.

Physical form

Ni-NTA agarose

Preparation Note

1year at -70C

Analysis Note

routinely evaluated by phosphorylation of histone H1 by cdk2/cyclin E

Other Notes

For Specific Activity data, refer to the Certificate of Analysis for individual lots of this enzyme.

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.




Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents



Cyclin E/CDK2: DNA Replication, Replication Stress and Genomic Instability
Fagundes R and Teixeira LK
Frontiers in Cell and Developmental Biology, 9, 774845-774845 (2021)



Numéro d'article de commerce international

RéférenceGTIN
14-475M04053252729942
14-47504053252743689